SCHEMBL3192209

SCHEMBL3192209

C/[C]=C(\C)C(C)=C(C)CCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3447972 1.00
SCHEMBL2971356 0.78
SCHEMBL2971353 0.78
SCHEMBL31607321 0.69 CES1 (0.44)
SCHEMBL18573862 0.67 CES2 (0.32)
SCHEMBL4989271 0.67 CES1 (0.45)
SCHEMBL2102369 0.65
SCHEMBL2102367 0.65
SCHEMBL27848848 0.65
SCHEMBL3841640 0.65 HDAC3 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796324-B2 Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-08-05 US disclosed
US-20120238607-A1 SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-09-20 US disclosed
US-8202895-B2 Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-06-19 US disclosed
US-20100261771-A1 SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed
US-20100029985-A1 Process AVECIA PHARMACEUTICALS LIMITED (GB) 2010-02-04 US disclosed
WO-2009037497-A1 PROCESS FOR PREPARING SULPHONAMIDES NPIL PHARMACEUTICALS (UK) LIMITED (GB) 2009-03-26 WO disclosed
WO-2009037416-A1 PROCESS FOR PREPARING SULPHONAMIDES NPIL PHARMACEUTICALS (UK) LIMITED (GB) 2009-03-26 WO disclosed
WO-2009019412-A1 RACEMISATION PROCESS FOR OBTAINING (1S,4S) N-METHYL-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENEAMINE (SERTRALINE) NPIL PHARMACEUTICALS (UK) LIMITED (GB) 2009-02-12 WO disclosed
US-7462731-B2 Processes for the preparation of heterocyclic hydroxyamines and intermediates and catalysts for use therein NPIL PHARMACEUTICALS (UK) LIMITED (GB) 2008-12-09 US disclosed
US-20080223287-A1 Plasma enhanced ALD process for copper alloy seed layers LAVOIE ADRIEN R 2008-09-18 US disclosed
EP-1339655-A1 TRANSFER HYDROGENATION PROCESS AND CATALYST Avecia Limited (GB) 2003-09-03 EP disclosed
US-6545188-B2 Catalytic hydrogenation a acetophenone compound or corresponding imine compound AVECIA LIMITED (GB) 2003-04-08 US disclosed
US-20020156282-A1 Transfer hydrogenation process and catalyst AVECIA LIMITED 2002-10-24 US disclosed
EP-0971865-B1 TRANSFER HYDROGENATION PROCESS AND CATALYST AVECIA LTD (GB) 2002-08-14 EP disclosed
WO-2002044111-A1 TRANSFER HYDROGENATION PROCESS AND CATALYST AVECIA LIMITED (GB) 2002-06-06 WO disclosed
EP-1210305-A1 TRANSFER HYDROGENATION PROCESS Avecia Limited (GB) 2002-06-05 EP disclosed
US-6372931-B1 CATALYST COMPRISING COMPLEX OF TRANSITION METAL, CHELATING LIGAND AND CYCLOPENTADIENYL GROUP AVECIA LIMITED (GB) 2002-04-16 US disclosed
WO-2001012574-A1 TRANSFER HYDROGENATION PROCESS AVECIA LIMITED (GB) 2001-02-22 WO disclosed
EP-0971865-A1 TRANSFER HYDROGENATION PROCESS AND CATALYST Avecia Limited (GB) 2000-01-19 EP disclosed
WO-1998042643-A1 TRANSFER HYDROGENATION PROCESS AND CATALYST AVECIA LIMITED (GB) 1998-10-01 WO disclosed